ArticleThe oncologist2026
Evaluation of the efficacy of topical cosmetic products in patients with hand-and-foot syndrome undergoing oncological treatments.
Article in The oncologist, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundHand-foot syndrome (HFS) is a complication of many anticancer therapies and negatively affects patients' quality of life (QoL). Currently, little data are available on using non-pharmacological skin products as standard therapy for HFS.
aimThis study aims to investigate whether a specific set of cosmetic products is effective for managing HFS skin side effects in cancer patients. MATERIALS AND
methodsThis single-arm study involved 53 cancer patients with grade 1 HFS undergoing chemotherapy, targeted, or hormonal treatments at the European Institute of Oncology. The study included a baseline visit and a follow-up visit 45 days later. All enrolled patients were prescribed a set of four cosmetic products for skin treatment. Patients underwent instrumental measurement to evaluate skin hydration and erythema, while their QoL was assessed using the Skindex-16 self-questionnaire. Additionally, physicians clinically evaluated the HFS severity, using the CTCAE (Common Terminology Criteria for Adverse Events) scale and by comparing patient photographs.
resultsNo patients worsened. After 45 days, the application of the cosmetic set increased skin hydration by 33% (P < .0001), while skin erythema decreased by 82.9% (P < .0001). Patients also showed a significantly lower mean Skindex-16 score at 45 days (-35.5%, P < .0001) compared to baseline. These findings were associated with clinical improvement in HFS-related skin symptoms in 58.5% of patients.
conclusionThese results show that a set of cosmetic products specific for cancer skin care can effectively manage HFS-related symptoms, resulting in improved QoL for patients, regardless of the anticancer treatment received.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.